8-K: Eyenovia Appoints Andrew Jones as New CFO Following Gandolfo's Retirement

Eyenovia, Inc. has appointed Andrew Jones as its new Chief Financial Officer, succeeding John Gandolfo who is retiring but will remain with the company for a transition period.

Summary

• Eyenovia, Inc. announced the retirement of its Chief Financial Officer, Treasurer, and Secretary, John Gandolfo, effective August 30, 2024.
• To ensure a smooth transition, Mr. Gandolfo will remain an employee of the company until November 30, 2024.
• Andrew D. Jones has been appointed as the new Chief Financial Officer, Treasurer, and Secretary, also effective August 30, 2024.
• Mr. Jones previously served as CEO and Treasurer of NovaBay Pharmaceuticals and has extensive experience in finance and accounting within the life sciences industry.
• Mr. Jones's initial annual salary will be $440,000, with a target bonus of 40% of his base salary.
• He will also receive an inducement equity award of options to purchase 200,000 shares of the company's common stock, vesting over four years.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the appointment of an experienced CFO and a smooth transition plan, but there are also risks associated with the change in leadership and the company's future performance.

Positives

• The appointment of Andrew Jones brings a seasoned financial executive with over 30 years of experience in the pharmaceutical and medical device industries.
• Mr. Jones has a track record of success in both operations and capital raising, which is beneficial for Eyenovia's growth.
• The smooth transition plan with Mr. Gandolfo remaining until November ensures continuity and knowledge transfer.
• The inducement equity award for Mr. Jones aligns his interests with the company's long-term success.

Negatives

• The departure of a long-term executive like John Gandolfo could create a temporary disruption, although the transition plan mitigates this risk.

Risks

• The company is relying on Mr. Jones's experience to navigate a critical data readout for MicroPine and the U.S. launch of clobetasol.
• There is a risk that the transition of responsibilities could impact the company's financial operations if not managed effectively.
• The company's future performance is dependent on the successful commercialization of its products and the development of its pipeline.

Future Outlook

The company is focused on the upcoming data readout for MicroPine, the U.S. launch of clobetasol, and the continued commercial ramp of Mydcombi. They are also looking to expand the use of their Optejet technology.

Management Comments

• Michael Rowe, CEO of Eyenovia, stated that Andrew Jones's experience is a perfect fit for the company at this crucial stage.
• Michael Rowe thanked John Gandolfo for his contributions since 2017 and wished him well in his retirement.
• Andrew Jones expressed excitement about joining Eyenovia and its potential to be a leader in topical ophthalmic medications.

Industry Context

This announcement reflects the ongoing need for experienced financial leadership in the competitive ophthalmic pharmaceutical industry, particularly for companies in the commercialization phase. Eyenovia is positioning itself for growth with the appointment of a CFO with a strong track record in the sector.

Comparison to Industry Standards

• The appointment of a CFO with experience at companies like NovaBay Pharmaceuticals and MyoScience is consistent with industry practice for companies at Eyenovia's stage.
• The compensation package for Mr. Jones, including a base salary of $440,000 and a 40% target bonus, is within the typical range for CFOs at similar-sized public companies in the biotech sector.
• The equity award of 200,000 shares with a four-year vesting schedule is a common incentive to align the CFO's interests with the long-term performance of the company.
• The transition plan with the outgoing CFO remaining for a few months is a standard practice to ensure a smooth handover of responsibilities.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially impacting the stock price.
• Employees will experience a change in leadership within the finance department.
• Customers and suppliers may not be directly impacted by this change.

Next Steps

• Andrew Jones will assume his responsibilities as CFO, Treasurer, and Secretary.
• John Gandolfo will assist with the transition until November 30, 2024.
• The company will focus on the upcoming data readout for MicroPine and the commercialization of its products.

Key Dates

Keywords

Chief Financial Officer, CFO, executive appointment, retirement, ophthalmic, pharmaceutical, finance, accounting, equity award, compensation